Page 42 - Rna News Today : Breaking News, Live Updates & Top Stories | Vimarsana

In its second big pharma deal to date, Shape Therapeutics Inc. drew Otsuka Pharmaceutical Co. Ltd. to the table in a potential $1.5 billion-plus collaboration initially aimed at developing gene therapies for ocular diseases. The multitarget agreement, which includes options for additional targets and tissue types, will combine Shape’s AI-driven adeno-associated virus (AAV) platform and Otsuka’s expertise in ophthalmology to develop intravitreally delivered AAV therapies.

With the rise of mRNA-based treatments, the field of oncology is about to go through a significant change.

Profund Advisors LLC acquired a new position in Avidity Biosciences, Inc. (NASDAQ:RNA – Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 57,365 shares of the biotechnology company’s stock, valued at approximately $881,000. Other hedge funds and other institutional investors have also […]

Avidity Biosciences, Inc. (NASDAQ:RNA – Get Free Report) shares reached a new 52-week low during mid-day trading on Thursday . The stock traded as low as $7.65 and last traded at $7.70, with a volume of 205688 shares. The stock had previously closed at $7.97. Analysts Set New Price Targets Several brokerages recently commented on […]

Largest organization of OB-GYNs in America accepted \ million from HHS to promote COVID-19 vaccines to PREGNANT WOMEN 08/30/2023 // Arsenio Toledo //